$1.32
7.79% yesterday
Nasdaq, Nov 25, 09:46 pm CET
ISIN
US04962H5063
Symbol
ATOS

Atossa Genetics Inc. Stock price

$1.28
-0.14 9.86% 1M
-0.18 12.33% 6M
+0.40 45.45% YTD
+0.47 58.08% 1Y
-1.01 44.10% 3Y
-0.11 7.58% 5Y
-153.81 99.17% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.06 4.92%
ISIN
US04962H5063
Symbol
ATOS
Sector

Key metrics

Market capitalization $161.03m
Enterprise Value $86.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.18
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-29.49m
Free Cash Flow (TTM) Free Cash Flow $-19.57m
Cash position $74.88m
EPS (TTM) EPS $-0.21
P/E forward negative
Short interest 10.15%
Show more

Is Atossa Genetics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Atossa Genetics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Atossa Genetics Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Atossa Genetics Inc. forecast:

Buy
100%

Financial data from Atossa Genetics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.03 0.03
200% 200%
-
-0.03 -0.03
200% 200%
-
- Selling and Administrative Expenses 13 13
5% 5%
-
- Research and Development Expense 16 16
2% 2%
-
-29 -29
3% 3%
-
- Depreciation and Amortization 0.03 0.03
200% 200%
-
EBIT (Operating Income) EBIT -29 -29
3% 3%
-
Net Profit -27 -27
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Atossa Genetics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atossa Genetics Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer
Neutral
GlobeNewsWire
6 days ago
Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen's ability to significantly reduce mammographic breast density to be featured at conference Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen's ability to significantly reduce mammographic breast density to be featured at conference
Neutral
GlobeNewsWire
14 days ago
SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced financial results for the fiscal quarter ended September 30, 2024, and provided an update on recent company developments.
More Atossa Genetics Inc. News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Quay
Employees 12
Founded 2008
Website www.atossatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today